{"id":"ciprofloxacin-dpi-bayq3939","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Dysgeusia (taste disturbance)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ciprofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The DPI (dry powder inhaler) formulation is designed for direct pulmonary delivery to treat respiratory tract infections.","oneSentence":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:58.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis-associated Pseudomonas aeruginosa lung infection (inhaled formulation)"},{"name":"Respiratory tract infections caused by susceptible gram-negative and gram-positive bacteria"}]},"trialDetails":[{"nctId":"NCT02661438","phase":"NA","title":"Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-01-12","conditions":"Bronchiectasis, Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT01764841","phase":"PHASE3","title":"Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05-02","conditions":"Bronchiectasis","enrollment":416},{"nctId":"NCT02106832","phase":"PHASE3","title":"Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-04-30","conditions":"Bronchiectasis","enrollment":521},{"nctId":"NCT00645788","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Cystic Fibrosis","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ciprofloxacin DPI (BAYQ3939)","genericName":"Ciprofloxacin DPI (BAYQ3939)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Cystic fibrosis-associated Pseudomonas aeruginosa lung infection (inhaled formulation), Respiratory tract infections caused by susceptible gram-negative and gram-positive bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}